"BD secures FDA 510 (k) clearance for EnCor EnCompass system" was originally created and published by Hospital Management, a ...

BD (NYSE: BDX) announced today that the FDA granted 510(k) clearance for its EnCore EnCompass breast biopsy and tissue ...

Becton, Dickinson and Co. will invest more than $110M to expand a Nebraska syringe facility, add 120 jobs and support ...

The FDA clears Becton Dickinson's EnCor EnCompass breast biopsy system, with a U.S. launch planned for early 2026.

BD (Becton, Dickinson and Company) has announced a $110m investment to expand its production of prefillable syringes in the ...

BD, a leading global medical technology company, and Frazier Healthcare Partners, a leading private equity firm focused exclusively on the healthcare sector, announced a definitive agreement for BD to ...

Waters Corp. and BD announced a definitive agreement July 14 to combine BD’s Biosciences & Diagnostic Solutions businesses with the Milford, Mass.-based company. The deal is structured as a ...

As the market for GLP-1 injections continues to grow, BD aims to ride that wave by providing drugmakers with its prefilled syringes. Biologic medications—including those blockbusters for diabetes and ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will host its virtual 2026 Annual Meeting of Shareholders (the "Annual Meeting") on ...

After racking up a string of acquisitions throughout 2022—including one of the medtech industry’s largest of the year in its $1.5 billion buyout of Parata Systems—BD has yet to make any major ...

Becton, Dickinson and Co. is increasing its U.S. manufacturing capacity for essential medical devices, including syringes, needles and IV catheters. As part of a $10 million investment in 2024, new ...